Therapeutic Area

Bladder Cancer

Therapeutic area intelligence for Bladder Cancer with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

AstraZeneca →

Merck →

Assets

Imfinzi →

KEYTRUDA →

Recent signals(3)

RegulatoryJune 17, 2026

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

The FDA has granted priority review for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for muscle-invasive bladder cancer.

ClinicalJune 16, 2026

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

The Phase III VOLGA trial demonstrated that perioperative Imfinzi plus neoadjuvant EV significantly improves event-free survival and shows a favorable trend in overall survival for muscle-invasive bladder cancer.

RegulatoryJune 16, 2026

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

The EU CHMP has issued a positive opinion for the combination of KEYTRUDA and Padcev as a treatment for cisplatin-ineligible muscle-invasive bladder cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Bladder Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.